Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

KOL Insight: Bladder Cancer [2020]

Product Code:
596201521
Publication Date:
August 2020
Format:
PDF + PPTX
Licence Type:
Multi-user licence

Therapy Trends KOL Insight: Bladder Cancer

KOLs expect Pfizer/Merck Group's Bavencio to be practice changing in the first-line maintenance treatment of locally advanced or metastatic urothelial cancer. But what impact will Bavencio have on the position of Merck & Co's Keytruda in the second-line setting? Will the new label extension for Keytruda in NMIBC and the prospect for combination therapy see it advance? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk

Key questions answered

  • Why are KOLs optimistic about the potential of Astellas/Seattle Genetics' antibody-drug conjugate, Padcev (enfortumab vedotin)?
  • What insights do KOLs have for Janssen, Bayer and QED Therapeutics if use of FGFR therapies for locally advanced or metastatic UC who have susceptible gene mutations, is to expand?
  • What are the expected benefits of novel intravesical therapies, such as FKD Therapies/Ferring's Adstiladrin (nadofaragene firadenovec) for patients with BCG-unresponsive NMIBC?
  • Which combinations might signal the future for immunotherapy in urothelial carcinoma?

Examples of Therapies Covered

Keytruda Tecentriq
Opdivo Imfinzi
Bavencio Sasanlimab
Balversa Padcev
Rogaratinib Infigratinib

Partial List of Participating KOLs

  • Professor of Medical Oncology and of Urology
    at Yale Cancer Center and Co-Director of the Signal Transduction Research Program, Yale University, New Haven, CT, USA
  • Professor at the Department of Genitourinary Medical Oncology,
    Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Medical Director of the Norris Cancer Hospital and Clinics, Head of the Section of Genitourinary Medical Oncology and Associate Professor of Medicine,
    Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, University of Southern California, CA, USA
  • Professor of Genitourinary Oncology,
    Director, Barts Cancer Centre, Lead for Solid Tumour Research, London, UK
  • Professor of Urology at the Amsterdam Academic Medical Center,
    Amsterdam, Netherlands
  • Professor of Urology,
    at a leading university hospital, Germany
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Email*
Job Title*
Phone*
Company Name *
Country Name *
Company
Job Function
Clean_Company
World_Region
FW_Sub_Type
ProductName
Brand_Name
Account Owner
Account_Type
Lead_Type
Product_Code
UID



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved